Huadong Medicine Receives FDA Clearance for HDM1005 Clinical Study in Obstructive Sleep Apnea
CompanyDeals

Huadong Medicine Receives FDA Clearance for HDM1005 Clinical Study in Obstructive Sleep Apnea

Laekna, Inc. Initiates IND-Enabling Study for Monoclonal Antibody LAE123 in Severe Diseases
CompanyDrug

Laekna, Inc. Initiates IND-Enabling Study for Monoclonal Antibody LAE123 in Severe Diseases

CORXEL Partners with Apeloa Pharmaceutical for CDMO Services Expansion
CompanyDeals

CORXEL Partners with Apeloa Pharmaceutical for CDMO Services Expansion

Wuhan Union Hospital to Transfer Hereditary Thrombophilia Detection Patent to Kingmed Diagnostics
CompanyDeals

Wuhan Union Hospital to Transfer Hereditary Thrombophilia Detection Patent to Kingmed Diagnostics

Shanghai Yanyin Technology Partners with Castalysis Bioscience to Advance CRISPR Software Development
CompanyDeals

Shanghai Yanyin Technology Partners with Castalysis Bioscience to Advance CRISPR Software Development

Eisai and Biogen Launch Alzheimer's Treatment Leqembi in South Korea
CompanyDrug

Eisai and Biogen Launch Alzheimer’s Treatment Leqembi in South Korea

Bayer AG Launches Bayer Co.Lab Berlin, Focusing on Life Science Innovation
Company

Bayer AG Launches Bayer Co.Lab Berlin, Focusing on Life Science Innovation

Chinese Pharmacopoeia Commission Approves Draft for ChP 2025 Edition
Policy / Regulatory

Chinese Pharmacopoeia Commission Approves Draft for ChP 2025 Edition

Huadong Medicine's Arcalyst Receives NMPA Approval for Cryopyrin-Associated Periodic Syndromes
CompanyDrug

Huadong Medicine’s Arcalyst Receives NMPA Approval for Cryopyrin-Associated Periodic Syndromes

Huadong Medicine's Elahere (Mirvetuximab Soravtansine) Approved by NMPA for Ovarian Cancer Treatment
CompanyDrug

Huadong Medicine’s Elahere (Mirvetuximab Soravtansine) Approved by NMPA for Ovarian Cancer Treatment

MicuRx Pharmaceuticals' MRX-4 Combo Shows Positive Results in Phase III Study
CompanyDrug

MicuRx Pharmaceuticals’ MRX-4 Combo Shows Positive Results in Phase III Study

National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs
Policy / Regulatory

National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs